TENIVAC is a 2 in 1 shot (tetanus and diphtheria) for persons over the age of seven (see Sanofi Pasteur product insert for recommended schedule and other indications).
- Vaccine Ingredients: Aluminum phosphate, formaldehyde, ammonium sulfate, sodium chloride, modified Mueller-Miller casamino acid medium without beef heart infusion, water.
- Estimated Efficacy: The efficacy of diphtheria toxoid in TENIVAC was based on the evaluation of immunogenicity (blood immune response) in 17 vaccine recipients tested after two and three doses of TENIVAC given as a primary series. All vaccine recipients were noted to have blood antibody levels considered to be protective against diphtheria four weeks following the third dose of TENIVAC. When administered as a booster dose, 100 percent of persons between the ages of 11-18 years, 99.2 percent of adults between 19 and 59 years of age and 88.0 percent of adults 60 years of age and older were noted to have the minimally acceptable blood antibody levels believed to be protective against diphtheria.
- Use with Other Vaccines: No clinical trials examined the safety or effectiveness of administering the vaccine with any other U.S. licensed vaccine.
Animal reproduction studies have not been conducted with TENIVAC. It is not known whether TENIVAC can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. TENIVAC has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.
